There are 1076 resources available
658P - Furmonertinib 160mg as first-line treatment for advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) exon 21 L858R mutation
Presenter: Meiqi Shi
Session: Poster Display session
Resources:
Abstract
659P - EGFR p.E709X point mutation in advanced NSCLC: Molecular characteristics and precise therapeutic strategy exploration
Presenter: Lanlan Pang
Session: Poster Display session
Resources:
Abstract
660P - Proteogenomic analysis of CSF reveals molecular patterns and potential drug targets of leptomeningeal metastases in EGFR+ NSCLC
Presenter: Meimei Zheng
Session: Poster Display session
Resources:
Abstract
661P - Prospective multi-institutional observational study of anti-PD-1/PD-L1 antibody (anti-PD-1/anti-PD-L1) re-treatment in patients with non-small cell lung cancer (NSCLC) previously treated with anti-PD-1/PD-L1 plus chemotherapy: NJLCG1901
Presenter: Hisashi Tanaka
Session: Poster Display session
Resources:
Abstract
662P - Comparison of atezolizumab/etoposide/platinum and durvalumab/etoposide/platinum for extensive-stage small cell lung cancer in Japan: A multicenter retrospective observational study
Presenter: Hiroyuki Sakashita
Session: Poster Display session
Resources:
Abstract
663P - Cisplatin (CDDP)+Etoposide (ETP)+Durvalumab (DUR) vs. Carboplatin (CBDCA)+ETP+Atezolizumab (ATZ): Propensity score matching (PSM) real-world data (RWD) on CDDP-fit extensive disease (ED)-small cell lung cancer (SCLC)
Presenter: Kosuke Hamai
Session: Poster Display session
Resources:
Abstract
664P - Chemotherapy combination regimens for EGFR-TKI resistant metastatic EGFR-mutated NSCLC: A systematic review and network meta-analysis
Presenter: Baodong Qin
Session: Poster Display session
Resources:
Abstract
665P - Real-world effectiveness and safety of first-line (1L) osimertinib for EGFR-mutated (EGFRm) advanced NSCLC: A prospective, multi-center, real-world study in China (FLOURISH Study)
Presenter: Jing Zheng
Session: Poster Display session
Resources:
Abstract
666P - First-line camrelizumab plus chemotherapy for brain metastases in NSCLC: The CTONG 2003 randomized controlled trial
Presenter: Jin-Ji Yang
Session: Poster Display session
Resources:
Abstract
667P - Furmonertinib 160mg as first-line treatment for metastatic EGFR mutation-positive non-small cell lung cancer (NSCLC) patients with central nervous system (CNS) metastases
Presenter: Yongchang Zhang
Session: Poster Display session
Resources:
Abstract